Coronavirus Notebook: Gilead Readies Remdesivir, China Expedites Clinical Approvals
Gilead is ramping up preparations to scale up remdesivir production, as China’s Genetic Materials Management Office expedites approvals for antiviral drugs and vaccine studies in China.
You may also be interested in...
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.